EGFR and non-small cell lung carcinoma: While it is known that EGFR-TKIs, including erlotinib, mainly benefit EGFR-mutated adenocarcinomas, a pooled analysis was conducted that demonstrated an efficacy of gefitinib for non-adenocarcinoma NSCLC patients harboring the EGFR mutation (8).